Death by bleomycin pulmonary toxicity in ovarian dysgerminoma with pathologic complete response to chemotherapy. A case report  by Calzas Rodríguez, Julia et al.
lable at ScienceDirect
Respiratory Medicine Case Reports 18 (2016) 48e50Contents lists avaiRespiratory Medicine Case Reports
journal homepage: www.elsevier .com/locate /rmcrCase reportDeath by bleomycin pulmonary toxicity in ovarian dysgerminoma
with pathologic complete response to chemotherapy. A case report
Julia Calzas Rodríguez a, *, María del Carmen Juarez Morales b,
Miguel Angel Racionero Casero b
a Department of Medical Oncology, University Hospital Fuenlabrada, Spain
b Department of Pulmonology, University Hospital Fuenlabrada, Spaina r t i c l e i n f o
Article history:
Received 24 November 2015
Received in revised form
14 April 2016
Accepted 15 April 2016
Keywords:
Ovarian dysgerminoma
Bleomycin
Pulmonary toxicity
Older patients
Pulmonary function testAbbreviations: OGCT, Ovarian germ cell tumors
toxicity; BEP, Bleomycin, Etoposide, Cisplatin; CT, com
* Corresponding author. Department of Medical O
Fuenlabrada, Camino del Molino 2, 28942 Fuenlabrad
E-mail address: jcalzas.hﬂr@salud.madrid.org (J. C
http://dx.doi.org/10.1016/j.rmcr.2016.04.004
2213-0071/© 2016 The Authors. Published by Elseviera b s t r a c t
With cisplatin-based chemotherapy, most patients with ovarian dysgerminoma will survive long-term.
Bleomycin is an important part of ovarian germ cell tumors (OGCT) treatment, and its dose-limiting
toxicity is the development of pulmonary toxicity and it is increased in patients older than 40 years.
We report the case of an elderly patient with an unresectable ovarian dysgerminoma who received
neoadjuvant chemotherapy and who developed fatal bleomycin pulmonary toxicity (BPT) after surgery. A
monitoring of pulmonary function is not routinely recommended for detecting BPT, although together
with carefully assessment for symptoms or signs suggestive of pulmonary toxicity is the best way to
reduce the risk of BPT. The frequency of pulmonary events in older patients makes us to think about the
possibility of either reduce the dose of bleomycin or removing it from the BEP in ovarian GCT.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Currently, ovarian dysgerminoma patients have an excellent
prognosis if treated according to modern principles, consisting of
chemotherapy with the BEP regimen (bleomycin, etoposide and
cisplatin) combined with adequate surgery. However the major
limitation of the therapy with bleomycin is the potential develop-
ment of an interstitial pulmonary ﬁbrosis life-threatening. We
report the case of an elderly patient with an unresectable ovarian
dysgerminoma, who achieved a pathologic complete response to
the neoadjuvant chemotherapy and developed a severe and fatal
pulmonary ﬁbrosis.2. Case report
A 62 years old woman non-smoker and without a medical his-
tory went to the emergency department with a strong pain in her
left lumbar zone. On examination, she presented a positive; BPT, bleomycin pulmonary
puted tomography.
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performed and it showed a retroperitoneal tumor located near left
kidney hilum (70  50  30 mm) with inﬁltration of renal vessels
and psoas muscle (Fig. 1). There were a lot of regional pathologic
lymph nodes and a left ovarian mass. The study was completed
with chest CT, that it was normal. A biopsy with thick needle of the
retroperitoneal tumor guided by ecography was performed. His-
tologic examination was consistent with dysgerminoma. The case
was assessed by gynecologic oncologists who rejected surgery by
unresectable bulky retroperitoneal tumor. She was sent to the
oncology department with the diagnosis of ovarian dysgerminoma
stage III (FIGO stage). Blood test showed high levels beta human
chorionic gonadotropin (BHGC 20 UI/L (0-5)) and lactate dehy-
drogenase (LDH 350 U/L (80-220)). The pulmonary function test
and diffusion capacity of carbon monoxide (DLCO) were normal.
Our patient started neoadjuvant chemotherapy with BEP (Bleo-
mycin, Etoposide, Cisplatin) every 21 days. After the ﬁrst cycle the
patient presented febrile neutropenia (it started colony stimulating
factors, and it continued in the next cycles like secondary pro-
phylaxis) and normalize the level of LDH y BHCG. After the third
cycle, the CT scan showed a partial response in retroperitoneal mass
(40  30  10 mm) and a complete response in the regional
pathologic lymph nodes and left ovary tumor. But in the thorax, it
revealed small ground-glass basal inﬁltrates in both lungs. A fourth
cycle without bleomycin was administered. A week later, thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Abdominal CT scan prior to treatment demonstrating a bulky retroperitoneal
tumor.
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dry cough. She presented ﬁne bibasilar crackles and hypoxemia.
Prednisone dose to 1 mg/kg/day, oxygen therapy and broad-
spectrum antibiotics was initiated. Pulmonary function tests
showed a diffusion lung capacity of carbon monoxide (DLCO)
markedly decreased to 30%. In the high-resolution chest tomogra-
phy the ﬁndings were compatible with a diffuse interstitial pneu-
monitis (clear-worsening compared to previous CT scan) (Fig. 2).
The bronchoscopy with alveolar washing was normal and without
diagnosis in the transbronchial biopsy.Fig. 2. High-resolution computed tomography of the chest showing diffuse interstitial
pneumonitis.In the following two months, the patient presented a progres-
sive respiratory clinic improvement with gradually decreasing
doses of corticoids, with improvement in the respiratory functional
and radiology tests. At that time, abdominal CT scan shows a
smaller and better delimited retroperitoneal tumor with a clear
separation of the aorta and psoas muscle. Finally, after a preoper-
ative assessment by anesthesia service, we decided interval
debulking surgery with curative purpose. The retroperitoneal mass
is removed hardly, but with optimal vascular and ureteral control. A
hysterectomy with bilateral salpingo-oophorectomy were per-
formed. After the operation, the patient began with acute dyspnea.
Complementary tests showed a severe hypoxemic respiratory
insufﬁciency and bilateral pulmonary inﬁltrates on chest radio-
graph. An acute respiratory distress syndrome was diagnosed.
Intubationwas required and connecting to invasive ventilation. The
patient had to be in the intensive care unit during three weeks
without possibility of extubation. Infection or inﬂammation were
excluded. The respiratory deterioration was attributed to a pro-
gressive pulmonary ﬁbrosis for bleomycin. Our patient ﬁnally died.
Pathologic examination revealed no viable tumor cells.
3. Discussion
Although the dysgerminoma is the most common malignant
germ cell tumor of the ovary, the OGCT are rare malignancies and
account for only about 2e3% of all malignant ovarian neoplasms.
The majority of cases (75%) are presented in adolescents and young
adults. Seventy-ﬁve percent of women with dysgerminomas are
presented with stage I disease. Due to its rarity, female GCT are
difﬁcult to study, and management is largely based on trials of male
GCT and epithelial ovarian cancer. It consisted of primary surgical
cytoreduction and after that, the chemotherapy. However, neo-
adjuvant chemotherapy followed by surgery is indicated for pa-
tients who are not surgical candidates at the time of diagnosis [2].
The 3e4 cycles BEP are recommended as the standard chemo-
therapy regimen for female GCT [1]. Germ cell tumors are a highly
curable malignancy. In fact, with the modern cisplatin-based
adjuvant chemotherapy (BEP), approximately 80% of patients who
present with advanced disease will be long-term survivors, even if
they have residual disease remaining after cytoreductive surgery. In
this report we described a case of dysgerminoma with an uncom-
mon clinical presentation: it arises in the 7th of life as a bulky
metastatic unresectable disease requiring chemotherapy before
surgery.
Unlike testicular cancer, clinical prognosticators of risk are less
well deﬁned for OGCT.
Age >40 at diagnosis, incomplete surgical resection, stage
higher than 1, and yolk sac histology have been suggested as high-
risk features [3,4]. The increased comorbidities, the reduced
treatment intensity combined with the increased therapy-related
toxicity might explain low survival in older women [5].
Bleomycin is an important part of GCT treatment but it is
associated with lung injury, including 1-3% fatal bleomycin-
induced pneumonitis [6]. The incidence bleomycin pulmonary
toxicity (BPT) is largely dependent on cumulative drug dose. A total
dose less than 300mg rarely causes BPT, whereas the risk increases
when the cumulative dose exceeds 400mg. So in trials of standard-
dose of chemotherapy for germ cell tumors (three or four cycles,
which contain a cumulative bleomycin dose of 270 or 360 mg
(units)), fatal pulmonary toxicity rates have been in the range of
0 to 1 and 0 to 3 percent, respectively. Other established risk factors
for the development of BPT are a reduced renal function (a low
glomerular function produces an increase the bleomycin half-life
leading to longer exposure of the lungs), cigarette smoking, chest
irradiation, prior lung disease and an older age [7]. The United
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treated with bleomycin-containing regimen for germ cell tumors,
with age over 40 was associated with a 2.3 fold higher risk of
pulmonary complications [8]. Our patient received a total dose of
bleomycin 270 mg(units), with a normal kidney function during all
the process, without ureter obstruction by the huge para-aortic
lymphadenectomy metastasis. In this case, the only risk factor for
the development of pulmonary toxicity was the age of the patient.
Among the perioperative risk factors of postoperative pulmonary
complication by bleomycin have been described the duration of
surgery, hyperoxia, volume and rate of ﬂuid administration and red
blood cell transfusion [9]. In a recent review of the patients who
had received a bleomycin chemotherapy and subsequently under-
went a major surgical procedure [10], the incidence of adult res-
piratory distress síndrome (ARDS) was only 1.3%.
No clinical study has assessed the efﬁcacy of Etoposide-
Platinum (EP) in ovarian GCT [11,12]. Based on data extrapolated
from the testicular cancer literature, rather than from prospective
trials in the malignant OGCT population, the use of EP can be
considered in patients who cannot receive bleomycin. At the time
of diagnosis, our patient had no absolute contraindications for
bleomycin treatment.
There is a paucity of data with no clear consensus regarding the
use of pulmonary function tests, particularly the carbon dioxide
diffusion capacity (DLCO), as a screening for lung toxicity during
therapy with a bleomycin-containing regimen. Some institutions
recommend to do only baseline pulmonary function test and only it
will be repeated if it is clinically indicated [1,13]. Other centers
perform serial monitoring of DLCO, before to each cycle, with
discontinuation of bleomycin when de DLCO decline >40% during
treatment [14,15].
4. Conclusions
Nearly all patients with advanced dysgerminoma treated with
chemotherapy are long term completed responders. However,
minimizing toxicity is necessary. Except the tight monitorizacion of
the kidney function in patients who received bleomycin, does not
exist a clinically predictive test of signiﬁcant bleomycin lung
toxicity. Nevertheless, monitoring of the lung function (DLCO/FVC
test) during treatment should be performed, mainly in patients
aged 40 years. In addition, avoiding or early stopping bleomycinin ovarian GCTs ovarian GCTs should be investigated, without
compromise the outcome.
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